Other ‘Seismic shift’ as obesity overtakes cancer for R&D returns PharmaphorumFor the first time in its 16-year history, Deloitte's annual report on pharma R D returns sees obesity replace cancer as the largest driver.Metabolic & GLP-1Read full story pharminent May 5, 2026 (Last updated: May 5, 2026) Pharmaphorum For the first time in its 16-year history, Deloitte’s annual report on pharma R D returns sees obesity replace cancer as the largest driver. Metabolic & GLP-1 Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Latus Bio secures $97m in funding to boost gene therapy accessNext: Lannett, Lanexa Biologics and Sunshine Lake secure FDA approval for Langlara Related Stories Other ASCO ’26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer pharminent June 2, 2026 Other ASCO26: Symptom-tracking app helps advanced cancer patients pharminent June 2, 2026 Other All eyes on Revolution, bispecific antibodies and more at ASCO26 pharminent May 26, 2026
